Choose a language and wait for the translated text.
Shots:
Alnylam has presented 5yr data from the P-III HELIOS-B study, incl. the 2yr OLE, evaluating Amvuttra (vutrisiran) vs delayed start (placebo switched to vutrisiran in OLE) in ATTR-CM patients at AHA 2026
Continuous treatment reduced the risk of all-cause mortality & recurrent CV events by 48% (monotherapy; n=395) & 41% (overall; n=654) & recurrent CV events by 50% & 41%, with better KCCQ-OS scores & NT-proBNP/troponin I stability; in patients on baseline tafamidis, recurrent CV events fell by 23%
A post hoc CPET analysis (n=48) showed preserved exercise capacity (peak VO₂ LS mean difference: 1.57 mL/kg/min vs placebo) over 2yrs; safety was consistent through 60mos
Ref: Business Wire | Image: Alnylam | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Alnylam Reports Five-Year P-III (HELIOS-B) Data of Amvuttra (Vutrisiran) for ATTR-CM at AHA 2026 appeared first on PharmaShots.
